Evidence map›Paper›PMID 37124537›Full record

ArticleFrontiers in oncology2023

Corrigendum: The

Xing Bian, Xiaolin Wang, Qiuyan Zhang, Liying Ma, Guozhen Cao, Ao Xu, Jinhua Han, Jun Huang, Wenchu Lin

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 67% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

  • Erratum for
    The2020
5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Xing BianHigh Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, China.
Xiaolin WangHigh Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, China.
Qiuyan ZhangThe CAS Key Laboratory of Innate Immunity and Chronic Disease, Innovation Center for Cell Signaling Network, School of Life Sciences, University of Science and Technology of China, Hefei, China.
Liying MaHigh Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, China.
Guozhen CaoHigh Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, China.
Ao XuThe First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Jinhua HanMOE Key Laboratory for Biosystems Homeostasis & Protection and Innovation Center for Cell Signaling Network, Life Sciences Institute, Zhejiang University, Hangzhou, China.
Jun HuangMOE Key Laboratory for Biosystems Homeostasis & Protection and Innovation Center for Cell Signaling Network, Life Sciences Institute, Zhejiang University, Hangzhou, China.
Wenchu LinHigh Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, China.
University of Science and Technology of China · CNZhejiang University · CNHefei Institutes of Physical Science · CNHigh Magnetic Field Laboratory · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fonc.2020.565820.].

Indexed as

BETDNA damage responseMYC paralogPARP1small cell lung cancer

Identifiers

PMID37124537
PMCPMC10132311
OpenAlexW4365143964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.